In patients with elevated PSA, the urinary MPS2 test had high accuracy for ruling out high-grade prostate cancer requiring biopsy. The urinary 18-gene MyProstateScore 2.0 (MPS2) test can detect ...

Valley Diagnostics secured exclusive global rights to patented biomarkers for prostate cancer, lung cancer, bovine ...

SAN FRANCISCO — A genomic test can identify patients with recurrent prostate cancer who are most likely to benefit from adding hormone therapy to secondary radiotherapy, according to findings ...

Urine panel had AUC of 0.96 and 0.92 with development and validation datasets, respectively, compared with 0.83 and 0.76 for urinary PCA3 RNA. HealthDay News — A urine-based biomarker panel has high ...

We performed a post hoc analysis of a single-center phase II trial (ClinicalTrials.gov identifier: NCT03503643) in which patients with unilateral grade group (GG) 2-4 PCa (n = 108) underwent hemigland ...

Researchers led by Keyi Li from the General Hospital of Northern Theater Command in Shenyang, along with international collaborators, detail significant advances in the identification and application ...

A third of patients with high-risk prostate cancer identified as biomarker-negative by an artificial intelligence (AI)–derived tool were safe to forgo long-term androgen deprivation therapy (ADT).

A high omega-3, low omega-6 diet with fish oil reduced the Ki-67 index by 15% in prostate cancer patients on active surveillance. The control group showed a 24% increase in the Ki-67 index, ...

New research links PSA and PSA density to long-term prostate cancer risk, supporting risk-adapted screening strategies. Learn more about the 20-year findings.

Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell Tumors We performed a post hoc analysis of a single-center phase II trial ...